Author | Patient No. | Age at intake | Type of infertility | BMI (kg/m2) | Basal AFC | AMH (μg/L) | Ovarian histology | E2 | FSH | Ig-FSHR | Infertility treatments before pregnant | Medication/hormonal pretreatment | Result |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amos, W. L., Jr. (1985) [12] | 1 | 41 | Secondary | NA | NA | NA | NA | NA | 88.4 IU/L | NA | HRT | Estrogens, medroxyprogesterone acetate | Liveborn |
Jequier, A. M. (1990) [6] | 2 | 28 | Secondarya | NA | NA | NA | NA | 31–52 pmol/L | 125 U/L | NA | HRT | 4 cycles (Mestranol + Norethisterone) | Liveborn |
3 | 30 | Secondarya | NA | NA | NA | normal ovarian stroma and follicles | 76 pmol/L | range seen in postmenopausal women | NA | HRT | Mestranol + Norethisterone | Normal pregnancy | |
Nawroth, F. and R. Sudik (1999) [8] | 4 | 32 | Secondary | NA | NA | NA | NA | NA | NA | NA | HRT | 2 mg estradiol valerate and 2 mg estradiol valerate/0.15 mg levonorgestrel | Liveborn |
Mueller, A., et al. (2003) [9] | 5 | 26 | Primary | NA | NA | NA | normal density of follicles | NA | 70 IU/L | NA | HRT | 2 mg estradiol valerate and 0.5 mg norgestrel per day administered sequentially | Liveborn |
Aslam, M. F., et al. (2004) [10] | 6 | 19 | Secondary | NA | NA | NA | NA | NA | 133.9 U/L | NA | HRT | 2 mg estradiol valerate and 0.5 mg norgestrel | Twice liveborn |
7 | 24 | Secondary | 27 | NA | NA | NA | NA | Higher than normal | NA | HRT | estradiol valerate and norgestrel | Normal pregnancy | |
Zielinska, D. and I. Rzepka-Gorska (2011) [11] | 8 | 31 | Secondary | NA | NA | NA | NA | 18.1 pg/ml | 58.2 IU/mL | NA | HRT | (spontaneous recovery of ovarian function after HRT) | liveborn |
Ezeh, U. I. O. and A. J. Breeson (1995) [7] | 9 | 32 | 22 | NA | NA | NA | NA | 39 pmol/L | 95–115 IU/L | NA | Ovarian Hyperstimulation | eight ampoules of menotrophin (Pergonal) daily for 14 days | Liveborn |
Rogenhofer, N., et al. (2015) [4] | 10 | 26 | Secondary | 22 | 15 | 2.1 | NA | 28.7 pg/mL | 50.8 U/mL | antibodies directed to hMG but not to recFSH | Controlled Ovarian Hyperstimulation and IVF | GnRH analogue Narfarelin, recombinant follitropin beta, hMG | liveborn |
Grynberg, M., et al. (2013) [13] | 11 | 29 | primary | normal | 23 and 18 | 4.50 and 4.36 | NA | < 15 | 40.3 and 38.4 mIU/mL | NA | IVM | 17ß-E2, hCG | liveborn |
Li, Y., et al. (2016) [14] | 12 | 33 | Secondarya | NA | 25 | 12.27 | NA | 260.57 pmol/l | 41.99 IU/L | NA | IVM | estradiol valerate, hCG | liveborn |
Galvao, A., et al. (2018) [15] | 13 | 29 | primary | 27.7 | 37 | 8.6 | NA | NA | 27.7 IU/L | NA | IVM | none | liveborn |
14 | 36 | primary | 18.9 | 40 | 2.11 | NA | NA | 7.9 IU/L | NA | IVM | HP-hMG 150 IU/day for 5 days, hCG | liveborn | |
15 | 23 | primary | 24.8 | 50 | 2.88 | NA | NA | 49.1 IU/L | NA | IVM | 17ß-E2, hCG | Twice liveborn | |
C. Flageole., et al. (2019) [23] | 16 | 31 | primary | NA | 19 | 3.24 ng/mL | NA | NA | 43–62 IU/L | NA | IVM | hMG (Menopur®) plus rFSH (Gonal F®), hCG | liveborn |